.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Accenture
Johnson and Johnson
Daiichi Sankyo
Teva
Cerilliant
McKinsey
Farmers Insurance
Chinese Patent Office
Boehringer Ingelheim

Generated: July 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,299,116

« Back to Dashboard

Which drugs does patent 8,299,116 protect, and when does it expire?


Patent 8,299,116 protects TORISEL and is included in one NDA. There has been one Paragraph IV challenge on Torisel.

Protection for TORISEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,299,116

Title:CCI-779 concentrate formulations
Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
Inventor(s): Rubino; Joseph T (Towaco, NJ), Siskavich; Victoria (Lyon Mountain, NY), Harrison; Maureen M (Sugar Loaf, NY), Gandhi; Pooja (Highland Mills, NY)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:13/206,641
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pf Prism Cv
TORISEL
temsirolimus
SOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes8,299,116*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Harvard Business School
Accenture
McKesson
Fuji
Julphar
Boehringer Ingelheim
Mallinckrodt
Teva
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot